Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Show episodes
151. Back to Basics - Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer
The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents. Studie
Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episo
This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensitive prostate cancer and the use of docetaxel in high and low-volume prostate cancer. Studies discussed in the episode: LA
As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive ca
Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway! Studie
It's been an "Olympic" ride to get here, and this is our penultimate breast cancer episode! Today, we talk about the BRCA mutations and how they impact both breast cancer and outcomes using targeted therapy. BRCA is a tumour suppressor gene. Today, we explore olaparib and its role in the adjuvant and metastatic setting